NOD (non-obese diabetic) mice spontaneously develop type 1 diabetes following T cell-dependent destruction of pancreatic β cells. Several alterations are observed in the NOD thymus, including the presence of giant perivascular spaces (PVS) filled with single-positive (SP) CD4⁺ and CD8⁺ T cells that accumulate in the organ. These cells have a decreased expression of membrane CD49e (the α5 integrin chain of the fibronectin receptor VLA-5 (very late antigen-5). Herein, we observed lower sphingosine-1-phosphate receptor 1 (S1P1) expression in NOD mouse thymocytes when compared with controls, mainly in the mature SP CD4⁺CD62L and CD8⁺CD62L subpopulations bearing the CD49e phenotype. In contrast, differences in S1P1 expression were not observed in mature CD49e⁺ thymocytes. Functionally, NOD CD49e thymocytes had reduced S1P-driven migratory response, whereas CD49e⁺ cells were more responsive to S1P. We further noticed a decreased expression of the sphingosine-1-phosphate lyase (SGPL1) in NOD SP thymocytes, which can lead to a higher sphingosine-1-phosphate (S1P) expression around PVS and S1P1 internalization. In summary, our results indicate that the modulation of S1P1 expression and S1P/S1P1 interactions in NOD mouse thymocytes are part of the T-cell migratory disorder observed during the pathogenesis of type 1 diabetes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983610PMC
http://dx.doi.org/10.3390/ijms19051446DOI Listing

Publication Analysis

Top Keywords

s1p1 expression
12
sphingosine-1-phosphate receptor
8
non-obese diabetic
8
type diabetes
8
decreased expression
8
nod mouse
8
mouse thymocytes
8
nod
6
expression
6
thymocytes
5

Similar Publications

Article Synopsis
  • * In a phase 2b trial (CARE), the effects of cenerimod dosages (2mg and 4mg) were evaluated in SLE patients, focusing on gene expression related to interferon and plasma cells after 6 months of treatment.
  • * Results indicated that the 4mg dosage of cenerimod significantly decreased interferon-associated biomarkers, especially in patients with high baseline interferon levels, supporting its selection for
View Article and Find Full Text PDF

Etrasimod (ADP334) is an oral, once-daily, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately to severely active ulcerative colitis and in development for the treatment of immune-mediated inflammatory diseases. Interaction between S1P and its five receptor subtypes (S1P-S1P) plays a role in several physiologic systems, including the cardiovascular and immune systems. Since differences in S1PR binding and downstream intracellular signaling could contribute to distinct profiles of drug efficacy and safety, we directly compared the S1P selectivity profile of etrasimod to three marketed S1PR modulators: fingolimod, ozanimod, and siponimod.

View Article and Find Full Text PDF

Sphingosine 1-phosphate (S1P) is a lysosphingolipid with antiatherogenic properties, but mechanisms underlying its effects remain unclear. We here investigated atherosclerosis development in cholesterol-rich diet-fed LDL receptor-deficient mice with high or low overexpression levels of S1P receptor 1 (S1P1) in macrophages. S1P1-overexpressing macrophages showed increased activity of transcription factors PU.

View Article and Find Full Text PDF

Inhibitory Fcγ receptor deletion enhances CD8 T cell stemness increasing anti-PD-1 therapy responsiveness against glioblastoma.

J Immunother Cancer

October 2024

Laboratory of Host Defenses, Department of Biological Sciences, KAIST, Daejeon 34141, Republic of Korea

Article Synopsis
  • Certain cancers, like glioblastoma (GBM), show resistance to immune therapies due to low mutation rates and a lack of immune response features, prompting research into enhancing T cells that possess stem-like properties.
  • Studies in mice tested the effectiveness of anti-PD-1 immunotherapy combined with strategies to maintain the activity of these stem-like T cells, revealing improvements in survival and immune response.
  • Results indicated that combining anti-PD-1 therapy with other treatments significantly increases the effectiveness of CD8 T cells, with the presence of tumor-specific memory T cells exhibiting strong stemness driving this enhanced antitumor response.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!